Call for Abstracts


Reshaping Surgical Oncology after COVID-19

Friday 23 October 2020, 16:00 - 21:00 CEST
Saturday 24 October 2020, 09:00 - 13:00 CEST


General Information & Deadlines

Abstract submission is now closed.

For any abstract related queries please contact the ESSO 2020 Virtual Conference Secretariat.

1. Abstracts may be submitted for the following scientific topics:

- COVID 19 AND SURGICAL ONCOLOGY (only original articles with real life data – no observation report)

2. Best abstracts will be selected for either oral presentation in one of the live sessions* or poster in the spotlight. The latter will consist of a 3 minute pre-recorded oral presentation.

3. Abstracts can be amended in the online submission system prior to the submission deadline of 11 September 2020. After the submission deadline, all abstracts will be automatically considered to be fully submitted and will proceed to the peer review.

4. The number of submitted abstracts is limited to 1 abstract per one presenting author.

5. Invited Speaker’s abstracts and all Selected abstracts will be posted on “ESSO 2020 Virtual” website and published in EJSO January or February 2021 issue (only for registered authors and if poster/slides/audio have been submitted on time). The copyright of the abstract remains with the author(s).

6. All presenting authors will be notified with the abstracts evaluation results by 24 September 2020.

7. All presenting authors are obliged to register for the ESSO 2020 Virtual meeting by 10 October 2020 (Nonregistered participant will not have their abstract presented nor published)
*Live sessions will not cover all tumour sites

Abstract Formatting

8. The abstract must be submitted in good English. The Scientific Committee reserves the right to reject abstracts which are presented in poor English or may request an immediate revision by the presenting author.

9. No more than 20 authors can be listed with only their institutional affiliation, city and country. Mailing addresses and academic degrees should not be mentioned. For co-operative study groups, the name of the group should be used instead of individual institutional affiliations or include the name of the group in the title of the abstract

10. The title of the abstract should be concise and accurately describe the study undertaken. Do not use non-standard abbreviations and commercial names (generic names only).

11. Abstracts should be structured to include the following 4 sections:

- Background: introductory sentence specifying the purpose of the study
- Material and methods: brief description of relevant experimental procedures
- Results: summary of the results of the investigation
- Conclusions: a statement of the main conclusions

12. The abstract submission system will not accept abstracts that exceed 2900 characters (including body of the abstract, spaces and 1 table).

13. Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.

Abstract Policies and Regulations

With the submission of an abstract to ESSO 2020 Virtual, the presenting author:
- Accepts responsibility for the accuracy of the submitted abstract.
- Accepts to be the contact person for all correspondence regarding the abstract and inform co-authors of its status.
- Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been published in the same format and with the same title prior to the date of the ESSO 2020 Virtual.
- States that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and informed consent given where appropriate.
- Identifies, obtains and discloses any financial interest in products or processes described in the abstract for all abstract authors. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research and other substantive relationships.